Physiomics awarded further contracts with Merck

Physiomics

0.71p

13:14 15/11/24

5.19%

0.04p

Oncology drug development consultancy Physiomics said on Friday that it had been awarded two further contracts by existing client Merck.

FTSE AIM All-Share

728.67

15:45 15/11/24

n/a

Health Care Equipment & Services

10,430.75

15:44 15/11/24

0.23%

23.76

Physiomics said the contracts, expected to be completed by the end of 2021, involved simulations of the clinical efficacy of drug products in Merck's DNA damage/repair portfolio.

Chief executive Dr Jim Millen said: "Merck remains a key, valued client and we are pleased to be continuing to work with them on a number of important development programs."

As of 0910 BST, Physiomics shares were down 0.66 at 6.06p.